GEN Exclusives

More »

GEN News Highlights

More »
Jul 10, 2007

OncoMethylome Enhances Pharmacogenomic Services in Deal with BioTrove

  • OncoMethylome Sciences will use BioTrove's OpenArray™ PCR screening technology in the development of DNA gene methylation cancer biomarkers.

    OncoMethylome products are designed to detect cancer cells and predict their response to cancer therapy by identifying specific methylation markers in patient DNA samples through PCR. "We look forward to enhancing our pharmacogenomic services with the BioTrove OpenArray system, which enables us to test our many proprietary methylation markers on clinical samples in a fast, high-throughput manner," says Wim Van Criekinge, vp, biomarker and pharmacogenomics research, OncoMethylome.

    Under the terms of the multiyear agreement, BioTrove will supply OncoMethylome with OpenArray nanoplates and instrumentation for use in R&D of DNA methylation-based biomarkers.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?